Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive    source : Investor.aveooncology.com    save search
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
Published: 2021-05-19 (Crawled : 21:00) - investor.aveooncology.com
AVEO | $15.0 0.0% 0 twitter stocktwits trandingview |
Health Technology
 | | O: 2.2% H: 3.16% C: -0.14%
phase 2 positive results positive results
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.